RAPT Therapeutics, Inc. (RAPT)

SEC fundamentals · as filed in 10-Q FY2025, period ended Sep 30, 2025 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$165.7M
Stockholders' Equity
$152.0M
Cash & Equivalents
$37.9M
Long-Term Debt
—

as filed in 10-Q FY2025, period ended Sep 30, 2025 · View filings on EDGAR ↗

In its 10-Q for the period ended Sep 30, 2025, RAPT Therapeutics, Inc. reported net income of -$17.6M and total assets of $165.7M. Every figure below is taken directly from RAPT Therapeutics, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2020–FY2023 · as reported

$5.0M-$55.9M-$116.8M
FY2020FY2021FY2022FY2023
Revenue$0Net income-$116.8M
FY2020 revenue
$5.0M
FY2023 revenue
$0

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2024—-$129.9M
FY2023$0-$116.8M
FY2022$1.5M-$83.8M
FY2021$3.8M-$69.2M
FY2020$5.0M-$52.9M
FY2019—-$43.0M
FY2018—-$36.1M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KMar 3, 2026on EDGAR ↗
8-KJan 20, 2026on EDGAR ↗
8-KJan 14, 2026on EDGAR ↗
8-KNov 28, 2025on EDGAR ↗
8-KNov 6, 2025on EDGAR ↗
10-QNov 6, 2025on EDGAR ↗
8-KOct 23, 2025on EDGAR ↗
8-KOct 20, 2025on EDGAR ↗
10-QAug 7, 2025on EDGAR ↗
8-KAug 7, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Sep 30, 2025 · 10-Q

Total Assets$165.7Msource ↗
Stockholders’ Equity$152.0Msource ↗
Cash & Equivalents$37.9Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Sep 30, 2025

Revenue—source ↗
Net Income-$17.6Msource ↗
Operating Income-$19.4Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$12.0Msource ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Sep 30, 2025

EPS (diluted)$-0.65source ↗
EPS (basic)$-0.65source ↗
Shares Outstanding27.7Msource ↗
Cash from Operations-$12.5Msource ↗
Cash from Financing$36,000source ↗
Cash from Investing$8.5Msource ↗

Restatement history

Point-in-time

No material restatements detected across 155 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.

Deeper fundamentals

A free API key reaches RAPT’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Get a free API key →See plans

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/RAPT

MCP tool: get_sec_fundamentals ticker=RAPT

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/RAPT/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=RAPT as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/RAPT/history

MCP tool: get_fundamentals_history ticker=RAPT

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/financial-health/RAPT

MCP tool: get_financial_health ticker=RAPT

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.